Navigation Links
New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
Date:12/10/2009

WASHINGTON, Dec. 10 /PRNewswire-USNewswire/ -- A new report released today by the National Pharmaceutical Council (NPC) provides guidance in the evaluation of comparative effectiveness research (CER), including easy-to-use "checklists" that help make sure such studies can be used to improve the dialogue between health care providers and patients, as well as better inform health care decision-making.

The report, "Demystifying Comparative Effectiveness Research: A Case Study Learning Guide," written by Robert W. Dubois, MD, PhD, chief medical officer of Cerner LifeSciences, and Sylvia L. Kindermann, MPH, Cerner LifeSciences senior research associate, discusses the three most prominent types of CER:

  • Randomized controlled trials (RCTs), wherein subjects in a population are randomly allocated into study and control groups to receive or not to receive an experimental intervention, such as a new therapeutic biopharmaceutical or medical device;
  • Meta-analysis, which synthesizes data across a series of similar studies, generally RCTs; and
  • Observational studies, which follow participants over a period of time to examine the potential associations between patients' exposure to treatment and health outcomes.

The report details a guide on how to best evaluate each kind of study, and it discusses case studies in each of the three types of CER.

"If conducted and interpreted correctly, these types of research can help to inform health care decision-making. If, however, such studies are conducted or interpreted incorrectly, the comparative answers from these studies may be inaccurate, or worse, misleading," Dubois and Kindermann note.

NPC released the report during a "Town Hall" meeting at AstraZeneca's Wilmington, Del., U.S. headquarters that was designed to help participants learn more about CER and explore how it can be designed to inform health care decision-making while sustaining innovation and patient access to needed medicines.

"There's so much written about CER, but very little written about how to properly evaluate a CER analysis. This report will help health care providers, patients and the media better understand what to look for so they can be better informed," said NPC President Dan Leonard.

In the "checklists," the authors suggest various questions, including:

  • For assessing a study's overall validity: "Is the study conducted in a 'real-world' setting?"
  • For randomized clinical trials: "Are study limitations discussed?"
  • For meta-analysis: "Were all relevant studies included?"
  • For observational studies: "Did the authors adequately describe and defend the statistical methods they used for analysis?"

The report is available on NPC's website at www.npcnow.org.

In addition to the new report, NPC has developed a CER toolkit that provides an overview of CER definitions, its history, and legislation currently under consideration. The toolkit is available in the issues section of NPC's website, www.npcnow.org, under "evidence-based medicine."

About the National Pharmaceutical Council

NPC's overarching mission is to sponsor and conduct scientific analyses of the appropriate use of biopharmaceuticals and the clinical and economic value of innovation. The organization's strategic focus is on evidence-based medicine (EBM) for health care decision-making, to ensure that patients have access to high-quality care. NPC was established in 1953 and is supported by the nation's major research-based pharmaceutical companies. For more information, visit www.npcnow.org.

SOURCE National Pharmaceutical Council


'/>"/>
SOURCE National Pharmaceutical Council
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees Choice New Product Awards
3. PRA International Hosts an Infectious Diseases Audio Conference
4. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
5. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
6. Reportlinker Adds Chiral Technology - International Technology & Market Trends
7. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
8. Swissray International Announces New Ownership
9. Chindex International to Present at Piper Jaffray Health Care Conference
10. SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts
11. Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... LONDON , Dec. 8, 2016 KEY ... for the largest share of the market in 2016 ... This dominance can be attributed to a large number ... region. (US hold the largest share in the patient ... several benefits such as reducing loss of blood during ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use ... nebulizer had a more child-friendly design, then children would be more likely to look ... to avoid the need to deliver medication via a nebulizer mask. The design will ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
Breaking Medicine News(10 mins):